Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2

Philip E. Castle, Mark Schiffman, Cosette M. Wheeler, Diane Solomon

Research output: Contribution to journalArticle

254 Citations (Scopus)

Abstract

Objective: To estimate the fraction of cervical intraepithelial neoplasia 2 (CIN 2) that might regress if untreated using data from the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS). Methods: We compared the cumulative occurrence of CIN 2 (n=397) and CIN 3 or more severe (n=542) diagnosed by the Pathology Quality Control Group in three trial arms-immediate colposcopy, human papillomavirus (HPV) triage, and conservative management-over the 2-year duration of the ALTS trial. A nonparametric test of trend was used to test for differences in the number of CIN 2 cases relative to number of CIN 3 or more severe cases across study arms with an increasing percentage of women referred to colposcopy at baseline. Results: There were no significant differences in the cumulative 2-year cumulative CIN 3 or more severe diagnoses by study arm (10.9%, conservative management; 10.3%, HPV; 10.9%, immediate colposcopy) (Ptrend=.8), but there was a significant increase in CIN 2 diagnoses (5.8%, conservative management; 7.8%, HPV triage; 9.9%, immediate colposcopy) (Ptrend<.001) in the study arms, with increasing number of women referred to colposcopy at baseline. The relative differences in cumulative CIN 2 by study arm among women who tested HPV-16 positive at baseline were less pronounced (Ptrend=.1) than women who tested positive for other high-risk-HPV genotypes (Ptrend=.01). Conclusion: There was evidence that approximately 40% of undiagnosed CIN 2 will regress over 2 years, but CIN 2 caused by HPV-16 may be less likely to regress than CIN 2 caused by other high-risk-HPV genotypes. Level of Evidence: II.

Original languageEnglish (US)
Pages (from-to)18-25
Number of pages8
JournalObstetrics and Gynecology
Volume113
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Cervical Intraepithelial Neoplasia
Colposcopy
Triage
Human papillomavirus 16
Genotype
Quality Control
Pathology
Control Groups

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. / Castle, Philip E.; Schiffman, Mark; Wheeler, Cosette M.; Solomon, Diane.

In: Obstetrics and Gynecology, Vol. 113, No. 1, 01.2009, p. 18-25.

Research output: Contribution to journalArticle

Castle, Philip E. ; Schiffman, Mark ; Wheeler, Cosette M. ; Solomon, Diane. / Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. In: Obstetrics and Gynecology. 2009 ; Vol. 113, No. 1. pp. 18-25.
@article{b4378fb1aed74521a142b411ae9b1471,
title = "Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2",
abstract = "Objective: To estimate the fraction of cervical intraepithelial neoplasia 2 (CIN 2) that might regress if untreated using data from the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS). Methods: We compared the cumulative occurrence of CIN 2 (n=397) and CIN 3 or more severe (n=542) diagnosed by the Pathology Quality Control Group in three trial arms-immediate colposcopy, human papillomavirus (HPV) triage, and conservative management-over the 2-year duration of the ALTS trial. A nonparametric test of trend was used to test for differences in the number of CIN 2 cases relative to number of CIN 3 or more severe cases across study arms with an increasing percentage of women referred to colposcopy at baseline. Results: There were no significant differences in the cumulative 2-year cumulative CIN 3 or more severe diagnoses by study arm (10.9{\%}, conservative management; 10.3{\%}, HPV; 10.9{\%}, immediate colposcopy) (Ptrend=.8), but there was a significant increase in CIN 2 diagnoses (5.8{\%}, conservative management; 7.8{\%}, HPV triage; 9.9{\%}, immediate colposcopy) (Ptrend<.001) in the study arms, with increasing number of women referred to colposcopy at baseline. The relative differences in cumulative CIN 2 by study arm among women who tested HPV-16 positive at baseline were less pronounced (Ptrend=.1) than women who tested positive for other high-risk-HPV genotypes (Ptrend=.01). Conclusion: There was evidence that approximately 40{\%} of undiagnosed CIN 2 will regress over 2 years, but CIN 2 caused by HPV-16 may be less likely to regress than CIN 2 caused by other high-risk-HPV genotypes. Level of Evidence: II.",
author = "Castle, {Philip E.} and Mark Schiffman and Wheeler, {Cosette M.} and Diane Solomon",
year = "2009",
month = "1",
doi = "10.1097/AOG.0b013e31818f5008",
language = "English (US)",
volume = "113",
pages = "18--25",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2

AU - Castle, Philip E.

AU - Schiffman, Mark

AU - Wheeler, Cosette M.

AU - Solomon, Diane

PY - 2009/1

Y1 - 2009/1

N2 - Objective: To estimate the fraction of cervical intraepithelial neoplasia 2 (CIN 2) that might regress if untreated using data from the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS). Methods: We compared the cumulative occurrence of CIN 2 (n=397) and CIN 3 or more severe (n=542) diagnosed by the Pathology Quality Control Group in three trial arms-immediate colposcopy, human papillomavirus (HPV) triage, and conservative management-over the 2-year duration of the ALTS trial. A nonparametric test of trend was used to test for differences in the number of CIN 2 cases relative to number of CIN 3 or more severe cases across study arms with an increasing percentage of women referred to colposcopy at baseline. Results: There were no significant differences in the cumulative 2-year cumulative CIN 3 or more severe diagnoses by study arm (10.9%, conservative management; 10.3%, HPV; 10.9%, immediate colposcopy) (Ptrend=.8), but there was a significant increase in CIN 2 diagnoses (5.8%, conservative management; 7.8%, HPV triage; 9.9%, immediate colposcopy) (Ptrend<.001) in the study arms, with increasing number of women referred to colposcopy at baseline. The relative differences in cumulative CIN 2 by study arm among women who tested HPV-16 positive at baseline were less pronounced (Ptrend=.1) than women who tested positive for other high-risk-HPV genotypes (Ptrend=.01). Conclusion: There was evidence that approximately 40% of undiagnosed CIN 2 will regress over 2 years, but CIN 2 caused by HPV-16 may be less likely to regress than CIN 2 caused by other high-risk-HPV genotypes. Level of Evidence: II.

AB - Objective: To estimate the fraction of cervical intraepithelial neoplasia 2 (CIN 2) that might regress if untreated using data from the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS). Methods: We compared the cumulative occurrence of CIN 2 (n=397) and CIN 3 or more severe (n=542) diagnosed by the Pathology Quality Control Group in three trial arms-immediate colposcopy, human papillomavirus (HPV) triage, and conservative management-over the 2-year duration of the ALTS trial. A nonparametric test of trend was used to test for differences in the number of CIN 2 cases relative to number of CIN 3 or more severe cases across study arms with an increasing percentage of women referred to colposcopy at baseline. Results: There were no significant differences in the cumulative 2-year cumulative CIN 3 or more severe diagnoses by study arm (10.9%, conservative management; 10.3%, HPV; 10.9%, immediate colposcopy) (Ptrend=.8), but there was a significant increase in CIN 2 diagnoses (5.8%, conservative management; 7.8%, HPV triage; 9.9%, immediate colposcopy) (Ptrend<.001) in the study arms, with increasing number of women referred to colposcopy at baseline. The relative differences in cumulative CIN 2 by study arm among women who tested HPV-16 positive at baseline were less pronounced (Ptrend=.1) than women who tested positive for other high-risk-HPV genotypes (Ptrend=.01). Conclusion: There was evidence that approximately 40% of undiagnosed CIN 2 will regress over 2 years, but CIN 2 caused by HPV-16 may be less likely to regress than CIN 2 caused by other high-risk-HPV genotypes. Level of Evidence: II.

UR - http://www.scopus.com/inward/record.url?scp=60749099876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60749099876&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e31818f5008

DO - 10.1097/AOG.0b013e31818f5008

M3 - Article

VL - 113

SP - 18

EP - 25

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 1

ER -